...By Paul Bonanos, Associate Editor FDA’s conclusion about data Reata added to a potentially registrational package...
...market cap, and could complicate the therapy’s path to U.S. approval.The agency said results from Reata’s...
...they received the drug from their results while receiving placebo during a randomized part of MOXIe.Reata...

...DRI Capital.Closer to Blackstone’s “bread and butter,” according to Galakatos, was its June deal with Reata Pharmaceuticals Inc....

...paying off for patients and investors.On Monday, Reata Pharmaceuticals Inc....
...companies each gained over 30% on Monday. Reata...
...market cap of about $850 million.Calliditas and Reata...

...include a new lease on life for Kodak, the latest from Akiko Iwasaki’s lab and Reata’s...
...Bio Inc. (NASDAQ:TBIO), and plans to start a Phase I trial by year-end. Repurposing Reata Reata Pharmaceuticals Inc....
...intended to reduce inflammation by restoring mitochondrial function, reducing oxidative stress and inhibiting pro-inflammatory signaling. Reata...

...and “growth investments” in emerging companies. In June, it made a $350 million investment in Reata Pharmaceuticals Inc....
...worldwide sales of chronic kidney disease therapy bardoxolone methyl by Reata or select partners (see “Reata...

...in Japan, China, Taiwan, South Korea and Southeast Asia. Figure: Reata chronicles Selected events for Reata Pharmaceuticals Inc....
...later that year, paying $400 million up front for Reata’s remaining NFE2L2 portfolio. In 2012, Reata...
...adverse events and mortality”, erasing billions from Abbott’s market cap (see “Reata, AIM, Backfire” ). Reata...

...research within the renal space, but is “going to look for business development opportunities there.” Reata Pharmaceuticals Inc....
...Phase III trial to treat chronic kidney disease caused by Alport syndrome (see “Data Set Reata...
...billion; analysts were expecting EPS of $16.19 on revenues of $25.51 billion. Elizabeth S. Eaton, Staff Writer Reata Pharmaceuticals Inc. Amgen...

...gain of $74.4 billion. Five companies more than doubled, with the biggest gain 179% by Reata Pharmaceuticals Inc....
...RX-3341 (Compound #), IV delafloxacin (Generic), Baxdela (Other) Regeneron Pharmaceuticals Inc. Gilead Sciences Inc. Sarepta Therapeutics Inc. Sage Therapeutics Inc. Reata Pharmaceuticals Inc. SanBio...

...Four companies led by Reata raised over $600 million in follow-ons ahead of Thursday’s trading session...
...in 244 offerings in 2017. About 190 companies have raised follow-ons to date in 2019. Reata Pharmaceuticals Inc....
...Alport syndrome (see “Bardoxolone Data Set Reata up to Advance Second Compound Toward Registration” ). Reata...

...Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial...
...its two most advanced compounds as it awaits registrational data in follow-on indications. On Tuesday, Reata Pharmaceuticals Inc....
...“Reata’s Pivotal Data in Friedreich Ataxia Point to Submissions” and “On Eve of Pivotal Data, Reata...